Assembly Biosciences Reports Second Quarter 2026 Financial Results and Recent Updates

– Expanded ABI-6250 clinical development into cholestatic liver diseases, including primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) – – Completed $115 million gross financing to support advancement of pipeline programs through key development milestones – – GS-1179 (formerly ABI-1179) selected to advance in HSV HPI program, with Phase 2 initiation expected by year-end 2026 – – Cash runway projected into 2029, including first $75 million Gilead collaboration extension p